Investment analysts at Evercore ISI began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued on Thursday, April 11th, Marketbeat.com reports. The firm set an “outperform” rating and a $175.00 price target on the biotechnology company’s stock. Evercore ISI’s price objective suggests a potential upside of 44.80% from the company’s previous close.
Several other equities research analysts have also recently commented on the company. Cowen restated a “buy” rating and issued a $213.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, March 31st. Piper Jaffray Companies boosted their target price on Sarepta Therapeutics from $200.00 to $208.00 and gave the company an “overweight” rating in a research note on Thursday, March 28th. BidaskClub cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, March 22nd. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 13th. Finally, BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Tuesday, March 12th. They issued an “outperform” rating on the stock. Three research analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus price target of $191.14.
Shares of SRPT opened at $120.86 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.21 and a quick ratio of 7.49. Sarepta Therapeutics has a 52-week low of $76.20 and a 52-week high of $176.50. The company has a market capitalization of $8.96 billion, a P/E ratio of -22.14 and a beta of 1.98.
In related news, CFO Sandesh Mahatme sold 65,000 shares of the business’s stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $145.00, for a total transaction of $9,425,000.00. Following the transaction, the chief financial officer now directly owns 73,649 shares of the company’s stock, valued at approximately $10,679,105. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.90% of the stock is currently owned by insiders.
Several hedge funds have recently bought and sold shares of SRPT. Janus Henderson Group PLC increased its holdings in shares of Sarepta Therapeutics by 44.9% during the 1st quarter. Janus Henderson Group PLC now owns 2,666,043 shares of the biotechnology company’s stock worth $317,766,000 after acquiring an additional 826,449 shares during the last quarter. FMR LLC grew its holdings in Sarepta Therapeutics by 6.9% in the 4th quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock valued at $1,152,977,000 after buying an additional 677,947 shares in the last quarter. Norges Bank acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $57,891,000. venBio Select Advisor LLC grew its holdings in Sarepta Therapeutics by 35.1% in the 4th quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock valued at $139,141,000 after buying an additional 331,500 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Sarepta Therapeutics by 104.7% in the 4th quarter. Bank of New York Mellon Corp now owns 570,668 shares of the biotechnology company’s stock valued at $62,277,000 after buying an additional 291,823 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors and hedge funds.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.